Hepatology News

LPCN 1148, an oral androgen receptor agonist, improved sarcopenia in men with advanced cirrhosis as early as week 12 — with sustained improvement through 52 weeks — and reduced recurrence of encephalopathy, according to late-breaking data.

Interim results from a global, multicenter study demonstrated the benefit of liver transplantation among patients with acute-on-chronic liver failure grades 2 and 3 and suggest that current allocation systems are inadequate.

As we enter the second half of 2024, it is important to understand some tax law changes that became effective this year and could affect your retirement savings and tax planning.

The AMA House of Delegates adopted several new policies to promote public health at its annual meeting.

BOSTON — Midlife women reporting bothersome hot flashes are more likely to receive a diagnosis of metabolic dysfunction-associated steatotic liver disease regardless of hormone therapy use, according to a speaker.

Over 2 years, bulevirtide monotherapy reduced the risk for decompensation and mortality, but not hepatocellular carcinoma, among patients with hepatitis D virus and compensated cirrhosis compared with untreated patients.

Patients with metabolic dysfunction-associated steatohepatitis who weigh more than 100 kg or a BMI more than 35 kg/m² had “slightly better” response with a 100 mg dose of Rezdiffra, according to data presented at EASL Congress.

The FDA granted accelerated approval to Ipsen Pharma’s Iqirvo 80 mg, a first-in-class oral, once-daily peroxisome proliferator-activated receptor agonist for the treatment of primary biliary cholangitis, according to a company release.

In a Healio video exclusive, Anu Osinusi, MD, MPH, reported long-term bulevirtide monotherapy 2 mg and 10 mg remained safe and effective for chronic hepatitis D virus with improved biochemical, fibrosis and virologic markers at 144 weeks.

At 15 years of follow-up, metabolic surgery “was not only safe” but also significantly reduced major adverse liver outcomes and decompensation in patients with metabolic dysfunction-associated steatohepatitis and compensated cirrhosis.